Imidafenacin NEW

$ 10.00 /1KG

Min. Order1KG
Purity99%
Cas No170105-16-5
Supply Ability5000000kg
Update time2023-07-28

Hebei Mojin Biotechnology Co., Ltd

5YR

Japan

Chemical Properties

Product Name	Imidafenacin
CAS No	170105-16-5
EC-No	689-703-7
Min. Order	1KG
Purity	99%
Supply Ability	5000000kg
Release date	2023/07/28

Product Name:	Imidafenacin
Synonyms:	ONO 8025;KRP-197; ONO-8025;Imidafenacin-d10;Staybla;Uritos;1H-IMidazole-1-butanaMide,2-Methyl-a,a-diphenyl-;IMidafenacin DISCONTINUED-PATENTED PRODUCT;4-(2-METHYL-1H-IMIDAZOL-1-YL)-2,2-DIPHENYLBUTANAMIDE
CAS:	170105-16-5
MF:	C20H21N3O
MW:	319.4
EINECS:	689-703-7
Product Categories:	Imidazoles, Pyrroles, Pyrazoles, Pyrrolidines;Amines;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:	170105-16-5.mol

Melting point	184-187°C
Boiling point	579.7±50.0 °C(Predicted)
density	1.12±0.1 g/cm3(Predicted)
storage temp.	Sealed in dry,Room Temperature
solubility	DMSO, Methanol
pka	15.72±0.50(Predicted)
form	Solid
color	White

Description

Imidafenacin, an M3/M1 muscarinic receptor antagonist, was introduced in Japan for the oral treatment of OAB. The majority of OAB symptoms are thought to result from overactivity of the detrusor muscle, which is primarily mediated by acetylcholine-induced stimulation of muscarinic M3 receptors in the bladder. Previously marketed muscarinic antagonists for OAB include propiverine, tolterodine, oxybutynin, trospium, darifenacin, and solifenacin. In vitro, imidafenacin is equally active against M1 and M3 receptors (K_b＝0.32 and 0.55nM, respectively), and approximately 10-fold less active against M2 receptors (K_b＝4.13nM).
Imidafenacin is chemically synthesized in three steps starting with alkylation of diphenylacetonitrile with dibromoethane, followed by condensation with 2-methylimidazole, and hydrolysis of the cyano group to a carboxamide group with 70% sulfuric acid.

Chemical Properties	White Solid
Originator	Kyorin (Japan)
Uses	A novel therapeutic agent for overactive bladder with antimuscarinic activity, on mediator release from urothelium and detrusor overactivity induced by cerebral infarction. A muscarinic antagonist.
Uses	Imidafenacin-d10 is deutirium labelled imidafenacin which is a novel therapeutic agent for overactive bladder with antimuscarinic activity, on mediator release from urothelium and detrusor overactivity induced by cerebral infarction.
Definition	ChEBI: Imidafenacin is a diarylmethane.